Association between ipilimumab and celiac disease

Mayo Clinic Proceedings

Volumn 88, Issue 4, 2013, Pages 414-417

  Gentile, Nicole M ^a   D'Souza, Anita ^a   Fujii, Larissa L ^a   Wu, Tsung Teh ^a   Murray, Joseph A ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BICALUTAMIDE; BUDESONIDE; IPILIMUMAB; LEUPRORELIN; MEPREDNISONE; PLACEBO; PREDNISONE; PROSTATE SPECIFIC ANTIGEN;

ADULT; ARTICLE; CASE REPORT; CASTRATION RESISTANT PROSTATE CANCER; CELIAC DISEASE; COLON BIOPSY; CYSTECTOMY; DIARRHEA; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG MEGADOSE; GLUTEN FREE DIET; HUMAN; HUMAN TISSUE; MALE; PHASE 3 CLINICAL TRIAL (TOPIC); PROSTATE ADENOCARCINOMA; RANDOMIZED CONTROLLED TRIAL (TOPIC);

EID: 84876563528     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mayocp.2013.01.015     Document Type: Article

References (8)

1. Weber JS, Kahler KC, Hauschild A. Management of immunerelated adverse events and kinetics of response with ipilimumab. J Clin Oncol. 2012;30(21):2691-2697.
2. Stein A, Voigt W, Jordan K. Chemotherapy-induced diarrhea: pathophysiology, frequency and guideline-based management. Ther Adv Med Oncol. 2010;2(1):51-63.
3. Rashtak S, Murray JA. Review article: coeliac disease, new approaches to therapy. Aliment Pharmacol Ther. 2012;35(7):768-781.
4. Scanlon SA, Murray JA. Update on celiac disease: etiology, differential diagnosis, drug targets, and management advances. Clin Exp Gastroenterol. 2011;4:297-311.
5. Simone R, Brizzolara R, Chiappori A, et al. A functional soluble form of CTLA-4 is present in the serum of celiac patients and correlates with mucosal injury. Int Immunol. 2009;21(9): 1037-1045.
6. Bardella MT, Marino R, Meroni PL. Celiac disease during interferon treatment. Ann Intern Med. 1999;131(2):157-158.
7. Weclawiak H, Ould-Mohamed A, Bournet B, et al. Duodenal villous atrophy: a cause of chronic diarrhea after solid-organ transplantation. Am J Transplant. 2011;11(3):575-582.
8. Rubio-Tapia A, Herman ML, Ludvigsson JF, et al. Severe spruelike enteropathy associated with olmesartan. Mayo Clin Proc. 2012; 87(8):732-738.